Jazz Pharmaceuticals appoints vice president of r&d
Jeffrey Tobias also takes chief medical officer role
Tobias has 20 years of experience in the biopharmaceutical industry across all phases of drug development, including regulatory filings in the US and Europe.
He has broad experience with a variety of therapeutic products spanning numerous clinical areas, including pain and neurological disorders.
Most recently, he was executive vice president of research and development at NeurogesX, where he has also been chief medical officer since 2005.
Prior to this Tobias was managing director of an independent biopharmaceutical consulting firm from 1996 to 2006, where he supported clients in all aspects of clinical development, technology assessment and strategic planning. He has also served in various roles in drug discovery and clinical development at ALZA, Chiron and XOMA.
Tobias also has 10 years of experience in clinical and academic medicine, focusing on internal and pulmonary and critical care medicine.
You may also like
Manufacturing
Continuous innovation: redefining the future of pharmaceutical manufacturing
In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced